Baylor study finds receptor called COUP-TFII may spark prostate cancer progression
Prostate cancer presents a dilemma for patients and the physicians who treat them. Which cancers are essentially indolent and present no risk and which are life threatening? Which can be watched and which need aggressive treatment? Researchers in the department of molecular and cellular biology at Baylor College of Medicine (home of the Dan L. Duncan Cancer Center), think a receptor called COUP-TFII that they have long studied may point the way to an answer. In a study that appears online in the journal Nature, they show that high levels (overexpression) of COUP-TFII can overcome a natural barrier to progression of prostate cancer, allowing tumor cells to grow and spread throughout the body – a process called metastasis.
Among the research institutions NCI funds across the United States, it currently designates 67 as Cancer Centers. Largely based in research universities, these facilities are home to many of the NCI-supported scientists who conduct a wide range of intense, laboratory research into cancer’s origins and development. The Cancer Centers Program also focuses on trans-disciplinary research, including population science and clinical research. The centers’ research results are often at the forefront of studies in the cancer field.